Headlands Technologies LLC Takes $1.63 Million Position in TransMedics Group, Inc. $TMDX

Headlands Technologies LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 24,599 shares of the company’s stock, valued at approximately $1,634,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Geode Capital Management LLC increased its holdings in TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after purchasing an additional 2,903 shares in the last quarter. Two Sigma Investments LP increased its holdings in TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after purchasing an additional 223,409 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of TransMedics Group by 43.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TMDX shares. Oppenheimer cut TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Weiss Ratings downgraded shares of TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. UBS Group reduced their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research note on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Wednesday, July 1st. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $124.18.

TransMedics Group Stock Performance

TMDX stock opened at $84.87 on Tuesday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a market cap of $2.93 billion, a PE ratio of 21.82 and a beta of 1.90. The business has a 50 day moving average of $79.23 and a 200-day moving average of $93.20. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business’s revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 earnings per share. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.